SANOFIBSESANOFI INDIA LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 4 Aug, 2026 · 20:10 IST

Sanofi India Q2 FY26: PAT rises 20%, margins improve to 27%

Revenue DeclineEbitda Margin ExpansionExceptional ItemResults View source PDFExplain this filing

SANOFI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.2%Reaction day
₹3395.00
prior close
₹3411.20
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-3.5% vs market
Pharmaceuticals peers, median of 165sector-0.0%-2.2% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.2
10m
-2.5
15m
-2.1
30m
-1.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.2+1.3-3.5-0.0-2.2
Next day
-1.2+1.6-2.8+0.2-1.4
2d
-1.3+1.7-3.0+0.4-1.7
3d
-1.9+1.6-3.5+1.1-3.0
4d
-2.8+1.5-4.2+1.2-4.0
5d
-4.8+1.8-6.6+1.0-5.8
1w
-4.7+2.1-6.8+0.5-5.2
15d
-6.1+3.2-9.2+0.2-6.2
1m
-8.1+3.7-11.8+1.7-9.8
2m
-11.0+1.1-12.2+1.2-12.2
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanofi India Q2 FY26 revenue grew 7.7% YoY to Rs 437.7 crore. PAT rose 20.1% to Rs 83.5 crore; EPS at Rs 36.26 vs Rs 30.18. PBT up 19% to Rs 112 crore; PBT margin improved to 27% from 24% on lower operating costs. Diabetes portfolio grew 14% with 58% value share. H1 revenue dipped 3.4% to Rs 910 crore. CFO Rachid Ayari to step down effective Sept 30, 2026.

Likely market impact

Margin expansion and profit growth signal operational discipline; diabetes franchise strength supports outlook despite modest top-line and CFO transition.